BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 18700128)

  • 1. Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream.
    Devirgiliis V; Panasiti V; Curzio M; Gobbi S; Rossi M; Roberti V; Calvieri S
    Dermatol Online J; 2008 Feb; 14(2):25. PubMed ID: 18700128
    [No Abstract]   [Full Text] [Related]  

  • 2. Facial extensive recurrent basal cell carcinoma: successful treatment with photodynamic therapy and imiquimod 5% cream.
    Requena C; Messeguer F; Llombart B; Serra-Guillén C; Guillén C
    Int J Dermatol; 2012 Apr; 51(4):451-4. PubMed ID: 22435437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodular basal cell carcinoma: when in doubt, cut it out.
    Brownell I
    J Drugs Dermatol; 2007 Dec; 6(12):1245-6. PubMed ID: 18189068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
    Roozeboom MH; van Kleef L; Arits AH; Mosterd K; Winnepenninckx VJ; van Marion AM; Nelemans PJ; Kelleners-Smeets NW
    J Am Acad Dermatol; 2015 Jul; 73(1):93-8. PubMed ID: 25935596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commentary on 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial'.
    Nijsten T
    Br J Dermatol; 2015 Jan; 172(1):12. PubMed ID: 25581586
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to 'Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal'.
    Arits A; Nelemans P; Kelleners-Smeets N
    Br J Dermatol; 2015 Jan; 172(1):11-2. PubMed ID: 25581585
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of pigmentation on photodynamic therapy.
    Apalla Z; Lallas A; Sotiriou E; Ioannides D
    Lancet Oncol; 2013 Aug; 14(9):e339-40. PubMed ID: 23896270
    [No Abstract]   [Full Text] [Related]  

  • 9. Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial.
    Roozeboom MH; Nelemans PJ; Mosterd K; Steijlen PM; Arits AH; Kelleners-Smeets NW
    Br J Dermatol; 2015 Mar; 172(3):739-45. PubMed ID: 25066012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing ablative fractionated resurfacing, photodynamic therapy, and topical imiquimod in the treatment of trichoblastomas of Brooke-Spiegler Syndrome: a case study.
    LoPiccolo MC; Sage RJ; Kouba DJ
    Dermatol Surg; 2011 Jul; 37(7):1047-50. PubMed ID: 21388481
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of pigmentation on photodynamic therapy - Authors' reply.
    Arits A; Kelleners-Smeets NW
    Lancet Oncol; 2013 Aug; 14(9):e340. PubMed ID: 23896273
    [No Abstract]   [Full Text] [Related]  

  • 12. Case study: Imiquimod 5% cream in the treatment of a large nodular basal cell carcinoma.
    Shulstad RM
    Dermatol Nurs; 2009; 21(2):86-7. PubMed ID: 19507375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison in real clinical practice of methyl aminolevulinate photodynamic therapy and surgery for small superficial basal cell carcinoma: 3-year recurrence rates and cosmetic outcomes.
    Sebaratnam DF; Venugopal SS; Murrell DF
    J Eur Acad Dermatol Venereol; 2011 Jan; 25(1):117-8. PubMed ID: 20456551
    [No Abstract]   [Full Text] [Related]  

  • 14. [Periocular basal cell carcinoma treatment tendencies].
    García Martín E; Fernández Tirado FJ
    Arch Soc Esp Oftalmol; 2010 Aug; 85(8):261-2. PubMed ID: 21130940
    [No Abstract]   [Full Text] [Related]  

  • 15. Sequential treatment of giant basal cell carcinomas.
    Madan V; West CA; Murphy JV; Lear JT
    J Plast Reconstr Aesthet Surg; 2009 Oct; 62(10):e368-72. PubMed ID: 18572004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma.
    Arits AH; Spoorenberg E; Mosterd K; Nelemans P; Kelleners-Smeets NW; Essers BA
    Br J Dermatol; 2014 Dec; 171(6):1501-7. PubMed ID: 24749843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The choice and measurement of fluence in photodynamic therapy for superficial basal cell carcinoma.
    van der Beek N; Bjerring P; Neumann HA
    Br J Dermatol; 2015 Oct; 173(4):1105-6. PubMed ID: 26146762
    [No Abstract]   [Full Text] [Related]  

  • 18. Photodynamic therapy and imiquimod immunotherapy for basal cell carcinomas.
    Nikkels AF; Piérard-Franchimont C; Nikkels-Tassoudji N; Bourguignon R; Piérard GE
    Acta Clin Belg; 2005; 60(5):227-34. PubMed ID: 16398319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating basal-cell carcinoma in a real life setting.
    Dummer R
    Lancet Oncol; 2013 Jun; 14(7):572-3. PubMed ID: 23683749
    [No Abstract]   [Full Text] [Related]  

  • 20. The choice and measurement of fluence in photodynamic therapy for superficial basal cell carcinoma: reply from the authors.
    Roozeboom MH; Arits AH; Kelleners-Smeets NW
    Br J Dermatol; 2015 Oct; 173(4):1106-7. PubMed ID: 26154079
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.